Toma Marieta I, Grosser Marianne, Herr Alexander, Aust Daniela E, Meye Axel, Hoefling Christian, Fuessel Susanne, Wuttig Daniela, Wirth Manfred P, Baretton Gustavo B
Institute for Pathology, University of Technology Dresden, D-01307 Dresden, Germany.
Neoplasia. 2008 Jul;10(7):634-42. doi: 10.1593/neo.08160.
Genetic aberrations are crucial in renal tumor progression. In this study, we describe loss of heterozygosity (LOH) and DNA-copy number abnormalities in clear cell renal cell carcinoma (cc-RCC) discovered by genome-wide single nucleotide polymorphism (SNP) arrays. Genomic DNA from tumor and normal tissue of 22 human cc-RCCs was analyzed on the Affymetrix GeneChip Human Mapping 10K Array. The array data were validated by quantitative polymerase chain reaction and immunohistochemistry. Reduced DNA copy numbers were detected on chromosomal arm 3p in 91%, on chromosome 9 in 32%, and on chromosomal arm 14q in 36% of the tumors. Gains were detected on chromosomal arm 5q in 45% and on chromosome 7 in 32% of the tumors. Copy number abnormalities were found not only in FHIT and VHL loci, known to be involved in renal carcinogenesis, but also in regions containing putative new tumor suppressor genes or oncogenes. In addition, microdeletions were detected on chromosomes 1 and 6 in genes with unknown impact on renal carcinogenesis. In validation experiments, abnormal protein expression of FOXP1 (on 3p) was found in 90% of tumors (concordance with SNP array data in 85%). As assessed by quantitative polymerase chain reaction, PARK2 and PACRG were down-regulated in 57% and 100%, respectively, and CSF1R was up-regulated in 69% of the cc-RCC cases (concordance with SNP array data in 57%, 33%, and 38%). Genome-wide SNP array analysis not only confirmed previously described large chromosomal aberrations but also detected novel microdeletions in genes potentially involved in tumor genesis of cc-RCC.
基因畸变在肾肿瘤进展中至关重要。在本研究中,我们描述了通过全基因组单核苷酸多态性(SNP)阵列发现的透明细胞肾细胞癌(cc-RCC)中的杂合性缺失(LOH)和DNA拷贝数异常。对22例人类cc-RCC肿瘤和正常组织的基因组DNA在Affymetrix GeneChip Human Mapping 10K阵列上进行分析。通过定量聚合酶链反应和免疫组织化学对阵列数据进行验证。在91%的肿瘤中检测到3号染色体短臂上的DNA拷贝数减少,32%的肿瘤中检测到9号染色体上的DNA拷贝数减少,36%的肿瘤中检测到14号染色体长臂上的DNA拷贝数减少。在45%的肿瘤中检测到5号染色体长臂上的DNA拷贝数增加,32%的肿瘤中检测到7号染色体上的DNA拷贝数增加。拷贝数异常不仅在已知参与肾致癌作用的FHIT和VHL基因座中发现,而且在含有假定新肿瘤抑制基因或癌基因的区域中也发现。此外,在对肾致癌作用影响未知的基因中,在1号和6号染色体上检测到微缺失。在验证实验中,90%的肿瘤中发现FOXP1(位于3p)的蛋白表达异常(与SNP阵列数据的一致性为85%)。通过定量聚合酶链反应评估,在57%和100%的cc-RCC病例中,PARK2和PACRG分别下调,在69%的cc-RCC病例中CSF1R上调(与SNP阵列数据的一致性分别为57%、33%和38%)。全基因组SNP阵列分析不仅证实了先前描述的大染色体畸变,而且还检测到了可能参与cc-RCC肿瘤发生的基因中的新型微缺失。